Eli Lilly and Company holds the cleaner structural position, with growth as the main driver and valuation adding further support. Novo Nordisk A/S still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup broadly confirms the structural lead — Eli Lilly and Company holds the more constructive position. That puts structure and market broadly in agreement — Eli Lilly and Company's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels.
Growth still does most of the heavy lifting in this comparison. Eli Lilly and Company leads by 10 points on the overall comparison score.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. LLY and NOVO-B.CO share the same industry classification.
For a similarity-based comparison, see how Eli Lilly and Company and Novo Nordisk A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
Structure clearly favours Eli Lilly and Company, even though current pricing leans the other way.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
One company is still expanding while the other is contracting, which creates a very wide growth split.
Absolute pricing still looks more supportive for Novo Nordisk A/S, with a forward P/E that is 10.8 turns lower there.
Growth settles the comparison, while pricing and valuation keep the broader setup from looking fully aligned.
Break down the LLY vs NOVO-B.CO comparison across all dimensions with the full interactive tool.
Explore how LLY and NOVO-B.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.